Last reviewed 2026-04-23 · How we verify

TETA 4HCL (60-<W108)

Orphalan · Phase 3 active Small molecule

TETA 4HCL (60-<W108) is a Potassium channel blocker Small molecule drug developed by Orphalan. It is currently in Phase 3 development for Atrial fibrillation for stroke prevention. Also known as: trientine tetrahydrochloride.

TETA 4HCL is a tetraethylammonium chloride, a potassium channel blocker.

TETA 4HCL is a tetraethylammonium chloride, a potassium channel blocker. Used for Atrial fibrillation for stroke prevention.

At a glance

Generic name	TETA 4HCL (60-<W108)
Also known as	trientine tetrahydrochloride
Sponsor	Orphalan
Drug class	Potassium channel blocker
Target	Potassium channels
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	Phase 3

Mechanism of action

TETA 4HCL works by blocking potassium channels in the heart, which can help to prolong the QT interval and prevent certain types of arrhythmias. This mechanism is thought to be beneficial in the treatment of atrial fibrillation for stroke prevention.

Approved indications

Atrial fibrillation for stroke prevention

Common side effects

Hypokalemia
QT interval prolongation
Arrhythmias

Key clinical trials

Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TETA 4HCL (60-<W108) CI brief — competitive landscape report
TETA 4HCL (60-<W108) updates RSS · CI watch RSS
Orphalan portfolio CI

Frequently asked questions about TETA 4HCL (60-<W108)

What is TETA 4HCL (60-<W108)?

TETA 4HCL (60-<W108) is a Potassium channel blocker drug developed by Orphalan, indicated for Atrial fibrillation for stroke prevention.

How does TETA 4HCL (60-<W108) work?

TETA 4HCL is a tetraethylammonium chloride, a potassium channel blocker.

What is TETA 4HCL (60-<W108) used for?

TETA 4HCL (60-<W108) is indicated for Atrial fibrillation for stroke prevention.

Who makes TETA 4HCL (60-<W108)?

TETA 4HCL (60-<W108) is developed by Orphalan (see full Orphalan pipeline at /company/orphalan).

Is TETA 4HCL (60-<W108) also known as anything else?

TETA 4HCL (60-<W108) is also known as trientine tetrahydrochloride.

What drug class is TETA 4HCL (60-<W108) in?

TETA 4HCL (60-<W108) belongs to the Potassium channel blocker class. See all Potassium channel blocker drugs at /class/potassium-channel-blocker.

What development phase is TETA 4HCL (60-<W108) in?

TETA 4HCL (60-<W108) is in Phase 3.

What are the side effects of TETA 4HCL (60-<W108)?

Common side effects of TETA 4HCL (60-<W108) include Hypokalemia, QT interval prolongation, Arrhythmias.

What does TETA 4HCL (60-<W108) target?

TETA 4HCL (60-<W108) targets Potassium channels and is a Potassium channel blocker.

Drug class: All Potassium channel blocker drugs
Target: All drugs targeting Potassium channels
Manufacturer: Orphalan — full pipeline
Therapeutic area: All drugs in Cardiovascular
Indication: Drugs for Atrial fibrillation for stroke prevention
Also known as: trientine tetrahydrochloride
Compare: TETA 4HCL (60-<W108) vs similar drugs
Pricing: TETA 4HCL (60-<W108) cost, discount & access